Swiss pharma Roche AG now expects stronger sales growth in 2018, raising its guidance for the year as its new multiple sclerosis medicine Ocrevus has quickly emerged as a competitive force in the U.S.
Sales of Ocrevus surged in the first quarter to total 479 million Swiss francs (roughly $485 million), making the drug's launch one of the best ever in the multiple sclerosis market, Roche said on Thursday.
